Recovery Report: Stanadyne Corp.'s Recovery Rating Profile Mar 12

  • ID: 2085128
  • March 2012
  • Standard & Poors
1 of 3


  • Stanadyne Corp.
  • Stanadyne Holdings Inc.
  • MORE

Standard & Poor's Ratings Services' has reviewed the recovery analysis on Windsor, Conn.-based Stanadyne Corp.'s senior subordinated notes and parent Stanadyne Holdings Inc.'s senior subordinate discount notes, in conjunction with our outlook revision. Our issue-level and recovery ratings remain unchanged. Our simulated default scenario contemplates lower-than-expected revenues and cash flow resulting from a depressed economy and loss of key customers. We believe that if Stanadyne defaulted, a viable business model would remain, and that lenders would achieve the greater recovery value through reorganization rather than through liquidation. At the end of third–quarter 2011, Stanadyne Corp. had $10.3 million drawn under a recently upsized $55.8 million asset-backed revolving credit facility (ABL), which is senior to its other debt, maturing in 2014....

Companies mentioned in this report are:
- Stanadyne Corp.
- Stanadyne Holdings Inc.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Stanadyne Corp.
- Stanadyne Holdings Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.